Company intelligence / Profile preview
Amplia Therapeutics Limited
Melbourne, Victoria, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase 2a ACCENT clinical trial of narmafotinib for advanced pancreatic cancer in Australia and South Korea. The first 26 patients have been recruited, with interim analysis expected around Q4 2024. Phase 1b established a safe and tolerable daily oral dose of 400mg for narmafotinib.
- Therapeutic areas
- OncologyPulmonologyRare Diseases
- Modalities
- Small moleculesOral inhibitors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Amplia Therapeutics Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amplia Therapeutics Limited.